Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: HER2/neu status of tumor cells at metastatic sites in patients with advanced disease may differ from that of the primary tumor. Assessing the presence of target antigens on circulating tumor cells (CTCs) might affect treatment choice. Patients and Methods: From June 2007 to October 2008, we collected 23 mL of blood from each of the 76 consecutive patients before and during chemotherapy to determine CTC numbers and HER2 overexpression. CTCs were isolated with the CellSearch System® (Veridex, LLC; Raritan, NJ) and fluorescently stained with the Epithelial Cell Kit®. Tumor Phenotyping Reagent® was used to investigate HER2/neu overexpression. Results: Concordance of HER2 status between the primary tumor and CTCs was 86% (49 out of 57 patients) at baseline and 82% (50 out of 61 patients) in the treatment samples. HER2 overexpression in CTCs was acquired in 8 out of 45 patients (18%) and lost in 3 out of 16 patients (19%) during a treatment containing trastuzumab. The overall discordance rate between the primary tumor and CTCs was 18% (11 out of 61 patients). Patients with HER2 overexpression in CTCs had poorer progression-free survival compared with those without CTCs or with HER2-CTCs (log-rank P =.036). Conclusion: Information on the presence or absence of HER2 overexpression can be obtained in CTCs. Larger trials are needed to evaluate the activity of HER2-targeted therapy in patients with acquired HER2 overexpression in CTCs.

Original languageEnglish
Pages (from-to)392-397
Number of pages6
JournalClinical Breast Cancer
Volume10
Issue number5
DOIs
Publication statusPublished - Oct 1 2010

Fingerprint

Circulating Neoplastic Cells
Breast Neoplasms
Neoplasms
Therapeutics
Disease-Free Survival
Cell Count
Epithelial Cells

Keywords

  • HER2/neu overexpression
  • Phenotype
  • Targeted therapy
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{22cbc736dc344d6785b27bd6b0fbafba,
title = "Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer",
abstract = "Background: HER2/neu status of tumor cells at metastatic sites in patients with advanced disease may differ from that of the primary tumor. Assessing the presence of target antigens on circulating tumor cells (CTCs) might affect treatment choice. Patients and Methods: From June 2007 to October 2008, we collected 23 mL of blood from each of the 76 consecutive patients before and during chemotherapy to determine CTC numbers and HER2 overexpression. CTCs were isolated with the CellSearch System{\circledR} (Veridex, LLC; Raritan, NJ) and fluorescently stained with the Epithelial Cell Kit{\circledR}. Tumor Phenotyping Reagent{\circledR} was used to investigate HER2/neu overexpression. Results: Concordance of HER2 status between the primary tumor and CTCs was 86{\%} (49 out of 57 patients) at baseline and 82{\%} (50 out of 61 patients) in the treatment samples. HER2 overexpression in CTCs was acquired in 8 out of 45 patients (18{\%}) and lost in 3 out of 16 patients (19{\%}) during a treatment containing trastuzumab. The overall discordance rate between the primary tumor and CTCs was 18{\%} (11 out of 61 patients). Patients with HER2 overexpression in CTCs had poorer progression-free survival compared with those without CTCs or with HER2-CTCs (log-rank P =.036). Conclusion: Information on the presence or absence of HER2 overexpression can be obtained in CTCs. Larger trials are needed to evaluate the activity of HER2-targeted therapy in patients with acquired HER2 overexpression in CTCs.",
keywords = "HER2/neu overexpression, Phenotype, Targeted therapy, Trastuzumab",
author = "Elisabetta Munzone and Franco Nol{\'e} and Aron Goldhirsch and Edoardo Botteri and Angela Esposito and Laura Zorzino and Giuseppe Curigliano and Ida Minchella and Laura Adamoli and Cassatella, {Maria Cristina} and Chiara Casadio and Sandri, {Maria Teresa}",
year = "2010",
month = "10",
day = "1",
doi = "10.3816/CBC.2010.n.052",
language = "English",
volume = "10",
pages = "392--397",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer

AU - Munzone, Elisabetta

AU - Nolé, Franco

AU - Goldhirsch, Aron

AU - Botteri, Edoardo

AU - Esposito, Angela

AU - Zorzino, Laura

AU - Curigliano, Giuseppe

AU - Minchella, Ida

AU - Adamoli, Laura

AU - Cassatella, Maria Cristina

AU - Casadio, Chiara

AU - Sandri, Maria Teresa

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Background: HER2/neu status of tumor cells at metastatic sites in patients with advanced disease may differ from that of the primary tumor. Assessing the presence of target antigens on circulating tumor cells (CTCs) might affect treatment choice. Patients and Methods: From June 2007 to October 2008, we collected 23 mL of blood from each of the 76 consecutive patients before and during chemotherapy to determine CTC numbers and HER2 overexpression. CTCs were isolated with the CellSearch System® (Veridex, LLC; Raritan, NJ) and fluorescently stained with the Epithelial Cell Kit®. Tumor Phenotyping Reagent® was used to investigate HER2/neu overexpression. Results: Concordance of HER2 status between the primary tumor and CTCs was 86% (49 out of 57 patients) at baseline and 82% (50 out of 61 patients) in the treatment samples. HER2 overexpression in CTCs was acquired in 8 out of 45 patients (18%) and lost in 3 out of 16 patients (19%) during a treatment containing trastuzumab. The overall discordance rate between the primary tumor and CTCs was 18% (11 out of 61 patients). Patients with HER2 overexpression in CTCs had poorer progression-free survival compared with those without CTCs or with HER2-CTCs (log-rank P =.036). Conclusion: Information on the presence or absence of HER2 overexpression can be obtained in CTCs. Larger trials are needed to evaluate the activity of HER2-targeted therapy in patients with acquired HER2 overexpression in CTCs.

AB - Background: HER2/neu status of tumor cells at metastatic sites in patients with advanced disease may differ from that of the primary tumor. Assessing the presence of target antigens on circulating tumor cells (CTCs) might affect treatment choice. Patients and Methods: From June 2007 to October 2008, we collected 23 mL of blood from each of the 76 consecutive patients before and during chemotherapy to determine CTC numbers and HER2 overexpression. CTCs were isolated with the CellSearch System® (Veridex, LLC; Raritan, NJ) and fluorescently stained with the Epithelial Cell Kit®. Tumor Phenotyping Reagent® was used to investigate HER2/neu overexpression. Results: Concordance of HER2 status between the primary tumor and CTCs was 86% (49 out of 57 patients) at baseline and 82% (50 out of 61 patients) in the treatment samples. HER2 overexpression in CTCs was acquired in 8 out of 45 patients (18%) and lost in 3 out of 16 patients (19%) during a treatment containing trastuzumab. The overall discordance rate between the primary tumor and CTCs was 18% (11 out of 61 patients). Patients with HER2 overexpression in CTCs had poorer progression-free survival compared with those without CTCs or with HER2-CTCs (log-rank P =.036). Conclusion: Information on the presence or absence of HER2 overexpression can be obtained in CTCs. Larger trials are needed to evaluate the activity of HER2-targeted therapy in patients with acquired HER2 overexpression in CTCs.

KW - HER2/neu overexpression

KW - Phenotype

KW - Targeted therapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=77957814298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957814298&partnerID=8YFLogxK

U2 - 10.3816/CBC.2010.n.052

DO - 10.3816/CBC.2010.n.052

M3 - Article

C2 - 20920984

AN - SCOPUS:77957814298

VL - 10

SP - 392

EP - 397

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 5

ER -